The study with lung cancer organoids showed that there was high correlation between drug screening with PDOs and patients’ mutation profiles.[7] Using lung cancer organoid model, we demonstrated that the lung cancer organoids retained the EGFR double mutation found in original cancer tissue, which suggests that lung cancer organoid may be utilized to predict the clinical response of the patient to targeted therapy as well as for clinical drug selection. The gene discussed is EGFR; the disease is lung cancer.